Pharma-Bio Serv, Inc.
PBSV · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.49 | -0.13 | 0.06 |
| FCF Yield | -5.45% | 9.65% | 2.90% | 3.25% |
| EV / EBITDA | -6.10 | 7.18 | 4.74 | -2.00 |
| Quality | ||||
| ROIC | -8.84% | 4.85% | 5.33% | -18.01% |
| Gross Margin | 26.46% | 29.84% | 25.16% | 26.65% |
| Cash Conversion Ratio | 0.73 | 1.44 | 0.59 | -0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.15% | -5.50% | -3.47% | 2,719,518.20% |
| Free Cash Flow Growth | -138.56% | 228.64% | -27.81% | -45.98% |
| Safety | ||||
| Net Debt / EBITDA | 5.94 | -7.70 | -11.40 | 4.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 37.52 | 39.76 | 52.78 | 32.03 |